Vima LLC Buys Shares of 5,054 CVS Health Co. (NYSE:CVS)

Vima LLC bought a new stake in shares of CVS Health Co. (NYSE:CVSFree Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 5,054 shares of the pharmacy operator’s stock, valued at approximately $399,000.

Several other institutional investors have also recently added to or reduced their stakes in CVS. SOA Wealth Advisors LLC. lifted its holdings in CVS Health by 4.9% in the fourth quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock worth $226,000 after purchasing an additional 133 shares during the period. Apella Capital LLC lifted its holdings in CVS Health by 4.2% in the fourth quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock worth $272,000 after purchasing an additional 136 shares during the period. Prairie Sky Financial Group LLC lifted its holdings in CVS Health by 4.1% in the fourth quarter. Prairie Sky Financial Group LLC now owns 3,612 shares of the pharmacy operator’s stock worth $285,000 after purchasing an additional 141 shares during the period. WealthShield Partners LLC lifted its holdings in CVS Health by 3.2% in the fourth quarter. WealthShield Partners LLC now owns 4,498 shares of the pharmacy operator’s stock worth $355,000 after purchasing an additional 141 shares during the period. Finally, Sugarloaf Wealth Management LLC lifted its holdings in CVS Health by 9.5% in the fourth quarter. Sugarloaf Wealth Management LLC now owns 1,639 shares of the pharmacy operator’s stock worth $129,000 after purchasing an additional 142 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

CVS stock traded down $0.81 during midday trading on Friday, hitting $60.22. The stock had a trading volume of 11,690,758 shares, compared to its average volume of 12,659,378. The firm has a market capitalization of $75.60 billion, a price-to-earnings ratio of 10.58, a P/E/G ratio of 0.57 and a beta of 0.53. CVS Health Co. has a 52 week low of $52.77 and a 52 week high of $83.25. The stock has a 50-day simple moving average of $61.51 and a 200 day simple moving average of $70.92. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVSGet Free Report) last issued its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing the consensus estimate of $1.69 by ($0.38). CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The firm had revenue of $88.44 billion during the quarter, compared to the consensus estimate of $89.33 billion. During the same period last year, the business earned $2.20 earnings per share. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, equities research analysts anticipate that CVS Health Co. will post 7.02 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Friday, April 19th. This represents a $2.66 annualized dividend and a yield of 4.42%. CVS Health’s dividend payout ratio is currently 46.75%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CVS. TD Cowen downgraded shares of CVS Health from a “buy” rating to a “hold” rating and cut their price target for the company from $99.00 to $59.00 in a report on Tuesday, May 7th. Baird R W raised shares of CVS Health to a “hold” rating in a research note on Thursday, May 30th. UBS Group downgraded CVS Health from a “buy” rating to a “neutral” rating and dropped their target price for the company from $85.00 to $60.00 in a report on Thursday, May 2nd. Truist Financial reiterated a “buy” rating and issued a $66.00 target price (down previously from $90.00) on shares of CVS Health in a report on Thursday, May 2nd. Finally, Leerink Partnrs downgraded CVS Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 1st. Eleven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $75.05.

Get Our Latest Research Report on CVS Health

Insider Activity

In other CVS Health news, Director Edward J. Ludwig bought 1,000 shares of the stock in a transaction dated Thursday, May 2nd. The stock was bought at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the completion of the purchase, the director now owns 21,630 shares in the company, valued at approximately $1,165,424.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.24% of the stock is currently owned by corporate insiders.

About CVS Health

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Featured Stories

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSFree Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.